Background and Aims Octoparms? is the first retrievable conical inferior vena cava filter (VCF) made in China. To investigate the safety and effectiveness of this VCF in prevention of pulmonary embolism (PE), this study was conducted for a non-inferiority comparison between this VCF and foreign imported VCF.Methods Using a randomized multicenter, positive parallel controlled design, the eligible patients with acute deep venous thrombosis (DVT) of lower extremities from 10 centers from September 2017 to March 2019 in China were enrolled and designated to study group and control group at a 1∶1 ratio. The variables concerning safety and effectiveness were compared between Octoparms? filter and USA Celect filter.Results A total of 188 patients were enrolled with 94 cases in each study group and control group. The baseline data of the two groups of patients were balanced, and all filters were successfully implanted. Filter was successfully retrieved in 87 cases (92.6%) in study group a the median retention time of 11 (7-31) d, and 26 cases (27.6%) thrombus interception. Filter was successfully retrieved in 91 cases (96.8%) in control group a the median retention time of 12 (7-21) d and 35 cases (37.2%) had thrombus interception. During the filter implantation and removal, no symptoms of PE occurred in both groups, and no severe filter shift or rupture was observed. The self-centering effect of filter in study group was better than that in control group (P<0.05). In the 104 cases (55.3%) undergoing thrombolytic therapy, the filter was not removed in 2 cases (1.9%) and the hemorrhage event occurred in 17 cases (16.3%); in the 84 cases (44.7%) who did not receive thrombolytic therapy, the filter was not removed in 8 cases (9.5%) and the hemorrhage event occurred 5 cases (5.9%). There were statistical differences in filter retrieval rate and incidence of hemorrhage event between patients with and without thrombolytic therapy (χ²=3.928, P=0.048; χ²=4.858, P=0.028).Conclusion Using Octoparms? conical VCF for prevention of PE is safe and effective, and the overall efficacy is similar with that of foreign imported VCF. In addition, thrombolytic therapy can effectively reduce the load of DVT and increase the filter removal rate, but it will increase the risk of hemorrhage in patients.